BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns [Seeking Alpha]
BriaCell Therapeutics Corp. - Common Shares (BCTX)
Company Research
Source: Seeking Alpha
Follow Summary BriaCell Therapeutics' lead candidate, Bria-IMT, shows promising trial results for metastatic breast cancer, potentially doubling overall survival and median progression-free survival. Despite a market cap below $30 million, BriaCell could tap into a $1-$5 billion market upon approval, with valuations between $1-$2 billion. Financing and shareholder dilution remain significant concerns, with recent offerings raising $18.5 million but also massively increasing the share count. The coming months may be interesting as the company moves closer to Phase 3 data. Analyst target of $15 implies over 1,000% upside; I maintain a Buy rating despite near-term financing uncertainties due to strong long-term potential. Maskot Thesis I have covered BriaCell Therapeutics ( NASDAQ: BCTX NASDAQ: BCTXW TSX: BCT:CA ) before in January 2023, and I am reissuing a Buy recommendation based on recent news and the latest progress. The company is currently in a Phase 3 trial w
Show less
Read more
Impact Snapshot
Event Time:
BCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCTX alerts
High impacting BriaCell Therapeutics Corp. - Common Shares news events
Weekly update
A roundup of the hottest topics
BCTX
News
- BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study [Yahoo! Finance]Yahoo! Finance
- BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer StudyGlobeNewswire
- BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference [Canadian Business Journal (Canada)]Canadian Business Journal
- BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference [Yahoo! Finance]Yahoo! Finance
- BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC ConferenceGlobeNewswire
BCTX
Earnings
- 6/14/24 - Beat
BCTX
Sec Filings
- 11/14/24 - Form SC
- 11/1/24 - Form 8-K
- 10/29/24 - Form 10-K
- BCTX's page on the SEC website